Introduction
Glaucoma is an optic neuropathy characterized by high intraocular pressure and retinal fibre layer damage, incurring visual field defects and even blindness if treated inadequately. 1 Glaucoma is also hetergeneous and multifactorial, in which the interaction of several environmental factors contributes to this ocular disease. 2 Juvenile-onset open angle glaucoma (JOAG) is a rare subtype of primary open-angle glaucoma (POAG) and characterized by an early age of onset (ranging between 5 and 35 years of age), severe elevation of intraocular pressure (IOP), and a strong genetic linkage with autosomal dominant inheritance. 3 Many clinicians confer that JOAG is different from common adult-onset glaucoma. 4 In addition, JOAG is distinguished from late congenital glaucoma and other childhood glaucomas by the absence of buphthalmos, Haab's striae and anterior segment dysgenesis. 3 To date, at least 14 gene loci (GLC1A-N) have been linked to POAG (OMIM #137760). Among these loci, three genes, MYOC encoding myocilin, OPTN encoding optineurin and the WDR36 gene encoding a protein of unknown function, seem to harbour the mutations that lead to POAG. [5] [6] [7] Additionally, CYP1B1 has been identified as a causative gene in primary congenital glaucoma (PCG) for nearly a decade. 7 Recent evidence has suggested the involvement of CYP1B1 mutations in several forms of glaucoma and anterior segment disorders. 8 On the basis of the above observations, CYP1B1 seems to have a wide role in ocular physiology.
CYP1B1 belongs to the CYP450 superfamily that contains 58 and 102 putatively functional genes in the human and mouse genome, respectively. Human CYP1B1 was the first gene in the CYP450 gene superfamily in which a mutation was demonstrated to be involved in a primary developmental defect. 9 Although it was mapped to chromosome 2p22-p21 by fluorescence in situ hybridization, the CYP1B1 gene contains three exons and two introns. Initiated in exon 2, the putative open reading frame was 1629 bp. 10 The CYP1B1 gene encoded a 543-amino-acid-long protein, including a membrane-bound region consisting of 53 residues in N-terminal, a 10-residue-long proline-rich region called a hinge, and a cytosolic globular domain consisting of 480 amino acids. 11 The CYP1B1 gene is expressed in several tissues, including the eye, as well as in the nucleus of several cell types, including tubule cells of the kidney and secretory cells of the breast. 12 In a recent study, mutations in MYOC and CYP1B1 genes were implicated in POAG and PCG, respectively. 13 Another study indicated that a digenic inheritance of CYP1B1 and MYOC mutations results in a phenotype with more pronounced glaucoma, suggesting that CYP1B1 may function as a gene modifier for the MYOC gene. 14 However, other studies indicated that CYP1B1 gene alone could be responsible for JOAG, in French, 15 Indian, 16 and Spanish 17 patients. A homozygous p.G61E missense mutation of CYP1B1 was also reported in the familial juvenile glaucoma. 18 The above studies demonstrate that CYP1B1 mutations potentially threaten JOAG and might also modify the glaucoma phenotype in patients who do not carry a MYOC mutation. Our previous study found that mutations of MYOC and OPTN are responsible for B12.5% of JOAG in the Taiwan population. 19, 20 However, exactly what causes the other 87.5% remains unclear. Further studies are warranted to determine whether other genes have mutations that account for a significant proportion of JOAG in the Taiwan population. Therefore, this study investigated the 5 0 -, 3 0 -untranslated (UTR) and coding regions of the CYP1B1 gene in 61 JOAG patients and 100 normal unrelated individuals, and tried to determine whether mutations in that gene are associated with the development of JOAG.
Materials and methods

Subject selection
A total of 61 individuals with JOAG were subjected to analysis of mutations in this study. 19, 20 Subjects with mutations in the MYOC gene were also included in the study. One hundred, randomly selected, normal individuals over 50 years of age were included as the control group from the Department of Aged Physical Checkup in the Chi Mei Medical Centre. Individuals in the control group also received complete ocular examinations, as described above, to exclude the possibility of glaucoma and other opthalmology disease. All of 161 individuals in the study, 61 patients and 100 controls, belong to the Han ethnic origin. The study protocol was approved by the Institutional Review Board (IRB) of Chi Mei Medical Centre and was carried out in accordance with the World Medical Association's Declaration of Helsinki (2000). All patients provided signed, informed consent to study participation, subsequent to the details of the study having been explained in detail to them.
Detection of the mutations of the CYP1B1 gene DNA samples were collected from 10 ml of peripheral blood acquired from each of the 161 individuals and purified using a Gentra DNA Blood Kit (Gentra Systems, Inc., Minneapolis, MN, USA), according to the manufacturer's directions. The quality and quantity of purified genomic DNA were determined by gel electrophoresis and spectrophotometry, respectively. Mutations in the 5 0 -,_3 0 -UTR and coding regions of the CYP1B1 gene were screened by direct sequencing (GenBank Accession No.NM_000104). Intragenic primers used for polymerase chain reaction (PCR) are listed in Table 1 . In brief, PCR was carried out in a reaction volume of 25 ml containing 100 ng of genomic DNA, 200 mM dNTP, 0.25 units of proTaq DNA polymerase (Promega Corporation, Madison, WI, USA), and 200 mM intragenic primers. The PCR products were purified using a PCR Purification Kit (QIAGEN GmbH, Hilden, Germany) and then subjected to PCR-directed DNA sequencing using a DNA Sequencing Kit (Applied Biosystems Corporation, Foster City, CA, USA). Sequencing was performed on an Applied Biosystems model 3730 automated sequencer (Applied Biosystems Corporation). Sequence data were compared with the published sequence of the CYP1B1 gene (GenBank Accession No.NM_000104).
Statistical analysis
Significant differences in allele frequencies between JOAG patients and controls were determined by the w 2 test. A P-value less than 0.05 represented a statistically significant difference between JOAG patients and controls.
Model building and structural-based analysis
Human CYP1B1 gene, which has been elucidated by X-ray crystallography (PDB entry 3PM0) to a resolution of 2.7 Å , provides a suitable template. 21 Threedimensional (3D) modelling of the human wild-type and p.R390H mutation were performed using SWISS-MODEL, an automated homology modelling program. The homology-modelling server SWISS-MODEL is directly accessible at http://swissmodel.expasy.org/ workspace/. 22, 23 This study used the automatic modelling approach to apply the complete protein sequence of human CYP1B1, including its 543 amino acids and its mutation, which are available in NCBI GenBank (NP_000095.2) in FASTA format. Data obtained by the homology models were visualized using Accelrys Viewer Lite version 5.0 (Accelrys, Inc., San Diego, CA, USA).
Results
Mutations in three exons of the CYP1B1 gene (GenBank Accession No.NM_000104), including flanking intronic sequences, 5 0 -UTR, 3 0 -UTR region and coding region, were screened by PCR amplification and direct DNA sequence analysis. Five polymorphic sites of the CYP1B1 gene were identified in the 61 JOAG patients and 100 unrelated normal controls ( Table 2 ). We made statistical w 2 test, comparison of the allelic frequencies on these polymorphic sites found in the JOAG patients and the controls. Allele frequencies of most polymorphisms between the patients and the controls were not different significantly (P4 0.05), except for variant c.403-13C4T (P ¼ 0.04 o0.05; Table 2 ).
Although none were found in the normal controls, two mutations of the CYP1B1 gene were identified in 3 of the 61 JOAG patients (Figure 1 ). The prevalence of CYP1B1 gene mutations in this study was 4.92% (3/61). A heterozygous c.1-313A4C mutation was found in one patient (1/61; 1.64%; Figure 1b ), and two patients had homozygous c.1169G4A mutation (2/61; 3.28%; Figure 1d ). Among the two mutations, the c.1169G4A mutations located in the coding region led to amino-acid changes within the CYP1B1 protein. c.1169G4A is a transversion mutation that leads to arginine (Arg; R)-histidine (His; H) substitution at codon 390 (p.R390H). Additionally, a heterozygous c.1-313A4C mutation was found in the 5 0 -UTR of CYP1B1 gene (Figure 1e ).
To understand the role and effect of the p.R390H missense mutation, we examined amino-acid sequences of CYP1B1 using a basic ConSeq analysis system (http:// conseq.tau.ac.il/). Following deposition of the protein sequence of CYP1B1 into the system, the system automatically detected homologous sequences of CYP1B1 and conducted multiple alignments. In total, 503 PSI-BLAST hits were detected by the system, of which 496 were unique sequences. Next step, the system automatically calculated the 50 sequences with the lowest E-values. Analytical results indicated that p.R390 residue is exposed and highly conserved (Conseq score ¼ 9) in the CYP1B1 protein of all species (Figure 2) .
To further study the protein-level mechanisms of the p.R390H mutation, a 3D model was constructed for a bioinformatic structural analysis. Analytical results revealed that the parallel orientation of side chains of Arg390 and Glu387 located at the helical K domain of CYP1B1, which are formed a hydrogen-bonding interaction with the turn-apart meander region end of Asn428 (Figure 3a) . This is expected to be involved in the haem-binding and proper folding of the molecule. While histindine (H) is to substitute arginine (R) at codon 390, we found that the parallel orientation of the Glu387 and His390 residues side-chain-interaction dramatically change to the end of Asn428. In contrast, Trp404 and His390 side-chain interaction was more transparent in the 3D molecular models (Figure 3b ). Therefore, we suggest that the p.R390H mutation may destroy the intramolecular structure of the CYP1B1 protein.
Previously studies show that both PolyPhen (Polymorphism Phenotyping) program and SIFT (Sorting tolerant from intolerant) algorithm methods can predict whether a single amino-acid substitution affects protein function. 24, 25 To assess the effect of p.R390H substitution, PolyPhen program and SIFT algorithm were also used in this study. Analytical results revealed that the PSIC (position-specific independent counts) score of p.R390H was 2.799 by PolyPhen program derived from multiple sequence alignment of observation. The PSCI score42.0 was predicted that p.R390H mutation is damaging, which is supposed to affect protein function and structure. In addition, the SIFT score of p.R390H was 0.0001. The score less than 0.05 was predicted to affect protein function. Therefore, we suggest that substitution at codon 390 from R to H is predicted to be deleterious for the protein function by SIFT server. On the basis of above results, we postulate that p.R390 has an important role in CYP1B1 protein. In particular, mutant p.R390H incurs a loss of function in the CYP1B1 protein.
This study also attempted to determine whether the c.1-313 A4C promoter variant affects the transcription level by predicting the transcription factor binding sites of CYP1B1 extended within 50 bps of up and down of the c.1-313 A4C promoter region, including the variant site, Figure 2 ConSeq predictions observed on human CYP1B1 (SWISS-PROT:Q16678 (CP1B1_Human)), using 50 homologues obtained from the Pfam database (family code: PF00067). The CYP1B1 protein sequence is displayed with the evolutionary rates at each site colour-coded onto it (see legend). The residues of the CYP1B1 sequence are numbered, starting from 1. The first row below the sequence lists the estimated burial status of the site (ie, 'b', buried versus 'e', exposed). The second row denotes the residues predicted to be structurally and functionally important: 's' and 'f', respectively. Vertical arrows represent amino-acid codons (p.R390).
based on use of the TFSEARCH prediction system (http://www.cbrc.jp/research/db/TFSEARCH.html). 26 No known transcription binding sites within this region were identified (data not shown).
Discussion
Nearly 100 mutations of CYP1B1 coding sequence have been found in patients with infantile congenital glaucoma among populations worldwide, including missense, nonsense, deletion, insertion or duplication mutations. 11, [27] [28] [29] [30] According to previous study, CYP1B1 significantly contributes to PCG, a rare and severely blinding disease with recessive inheritance. 11 Recent studies also indicated that the CYP1B1 gene alone could be responsible for POAG or JOAG patients. [15] [16] [17] In this study, five variants of the CYP1B1 gene were found in the 61 JOAG patients and in the 100 unrelated normal controls. These sequence changes are not classified as causative mutations, but as polymorphisms, because the frequencies were similar between the patient and normal control groups. Therefore, these polymorphic sites alone did not provide any significant evidence of association with JOAG risk. However, we cannot rule out the possibility that an unrecognized difference in ancestry may exist between the case and control groups, or that the variants are in linkage disequilibrium with a true disease-causing variant nearby. In addition, 3 of the 61 (3/61, 4.92%) JOAG patients carried mutations of the CYP1B1 gene, including c.1-313A4C and c.1169G4A (p.R390H) mutation. Despite having a low frequency, those mutations were undetected in the 100 normal controls. Although previous studies have described CYP1B1 mutation as a modifier of the MYOC gene in the development of the glaucomatous process, 31,32 we did not find that the mutations of both MYOC and CYP1B1 were simultaneously presented in the same JOAG patient from this study and our previous study. 19 Previously, p.R390H missense mutation has been described in one PCG case. 33 Located in the conserved alpha helix K domain, the arginine (R) 390 residue forms the consensus sequence GluXXArg, which is conserved among all members of the cytochrome P450 superfamily. 33 Similarly, our results indicated that p.R390 residue is highly conserved in the alpha helix K domain using the ConSeq server. ConSeq, a website server, can identify biologically important residues in a protein sequence. 34 On the basis of this finding, the transversion of Arginine to Histidine at codon 390 of the CYP1B1 profoundly impacts the function of the CYP1B1 protein.
The 3D characterization of protein structures must be improved to elucidate the functions of proteins and their disease-formation relationships. 22, 35 High-resolution characterization of proteins can be provided by either Figure 3 Bioinformatic estimation of the 3D structure of p.R309H CYP1B1 protein using human wild-type CYP1B1 protein (PDB ID 3PM0) as a template. Comparing the protein secondary structure architectures reveals the intra-molecular interactions between wildtype (a) and p.R390H mutation (b) in monomeric CYP1B1. Secondary structures are drawn with red solid ribbons (a-helices), blue ribbons (b-sheets) and white loops (turns). The yellow boxes present the close-up views of the 'meander' region defined by a previous study focus on the C-terminal of theme-binding domain in a similar orientation and key residues as in ball-and-stick representation. Hydrogen bonding is denoted by dash lines. The highly conserved residues region, including Glu387, Arg390, and Asn428 located on helical turn apart, which was contributed from a hydrogen-bonding interaction to stabilize the 'meander' region structure, is essential for normal functioning of the P450 molecule.
experimental methods such as X-ray crystallography and nuclear magnetic resonance or by computational analysis. 35 According to a previous prediction, the presence of p.R390 at conservation of this motif position is essential for the normal function of the CYPB1 molecule. 33 In addition to altering the side-chain characteristics from linear guanidinium group to imidazole ring, the point mutation of p.R390H affects the formation of salt bridges located on the 'meander' region, which is essential for normal functioning of the CYP1B1 molecule. 33 A recent study determined human CYP1B1 based on X-ray crystallography to 2.7 Å resolution with a-naphthoflavone bound in the active site cavity. 21 The structure of human CYP1B1 by X-ray diffraction can provide further insight into functional similarities and differences exhibited by family I P450s. 21 Without the p.R390H missense mutation crystallographic structure, this study developed a mutation molecular 3D model structure of human CYP1B1 protein by using a simulated model with human CYP1B1 protein (PDB ID is 3PM0) as a template and an automatic SWISS-MODEL homology modelling program. 23 As the most accurate computational method to generate reliable structural models, homology modelling is conventionally used in many biological applications. 20 Homology models of a protein of interest are a valuable means of interpreting sequence variations and designing mutagenesis experiments to elucidate the biological functions of proteins. 36, 37 This study has established that these highly conserved residues in alpha-helix K domain region including Glu387, Arg390, and Asn428 located on helical turn apart, which was created from a hydrogenbonding interaction to stabilize the 'meander' region structure, are essential for the normal function of the CYP1B1 molecule. The above results are similar and further confirm the previous prediction results. 33 In addition, we found that p.R390 is important positions in the CYP1B1 protein sequence using PolyPhen program and SIFT algorithm prediction methods. p.R390 residue was conserved throughout evolution and, therefore, substitutions at these positions may affect protein function. Our clinical and gene analysis data reveal the mutation of this residue, p.R390H, in two patients with JOAG. Therefore, our prediction results obtained by homology modelling, PolyPhen program and SIFT algorithm prediction methods can elucidate the functional deficiencies of CYP1B1 to cause glaucoma.
Thirteen variants of 5 0 -UTR in the CYP1B1 gene have been described so far (http://www.ensembl.org/ Homo_sapiens/Gene/Variation_Gene/). Conversely, this study did not detect any of the above-mentioned variants. Instead, a novel variant, c.1-313A4C, was identified in one of our patients. We believe that differences between the variants of CYP1B1 are possibly owing to racial variation. The c.1-313A4C variant is located within the promoter region. A variant of promoter generally influences (upregulated or downregulated) the initiation of transcription. The influence of this variant at the transcript cannot be eliminated, despite the lack of known transcription binding sites within 50 bp of up and down the c.1-313A site in our prediction assay by bioinformatics. Additionally, the variants of CYP1B1 were undetected in the 100 normal controls. Therefore, we posit that c.1-313A4C variant may be associated with JOAG. However, exactly how this variant affects the transcription and the promoter activity must be further understood, to more thoroughly understand the pathogenic role of CYP1B1 c.1-313A4C variant in JOAG. Finally, we have provided comprehensive genetic information on the CYP1B1 from study subjects with JOAG in Taiwan. Our results indicate that mutations of CYP1B1 gene are responsible for about 4.92% (3/61) of JOAG in the population of Taiwan. Therefore, CYP1B1 gene likely is not a major genetic factor underlying JOAG. In addition, our previous results found that mutations in MYOC and OPTN gene of JOAG patients are B12.5% in the Taiwan population. 19, 20 Therefore, about 17.42% of JOAG patients were found at least a risk factor for JOAG development in the population of Taiwan. However, the cause of the remaining 82.58% remains elusive. Further studies are necessary to determine whether there are other gene mutations or evironmental risk factors for JOAG in the population of Taiwan.
Summary
What was known before K Glaucoma is one of the leading causes of blindness in the world. Juvenile-onset open-angle (JOAG) is a subtype of glaucoma. In recent studies, mutations in MYOC and CYP1B1 genes were implicated in POAG, PCG and JOAG, respectively. However, little is known about the contribution of variants in the CYP1B1 gene to JOAG in Taiwan.
